Preference research overview
US Breast Cancer HCPs, n=300. Indices compare each slice to the full sample (100 = average).
Respondents
300
US oncologists & hem-oncs
Community
156
52% of sample
Academic
143
48% of sample
Research-active
164
55% of sample
>50 BC pts/mo
118
39% of sample
Sample composition
Setting
- Community156 · 52%
- Academic143 · 48%
- Other1 · 0%
Experience
- Experienced212 · 71%
- Early-career88 · 29%
Volume
- Very-high (50+)118 · 39%
- High (26–50)77 · 26%
- Mid (10–25)66 · 22%
- Low (1–9)39 · 13%
Research
- Research-active164 · 55%
- Not research-active88 · 29%
- Unknown48 · 16%
Top information sources
- Peer-reviewed journals83%i100
- Discussions with peers83%i100
- Accredited Continuing Medical Education (CME) programs79%i100
- Clinical guideline websites69%i100
- Discussions with pharmaceutical company medical representatives (Medical Science Liaisons)58%i100
- Medical news websites52%i100
- In-person medical congresses51%i100
- AI tools/generative AI platforms (e.g., ChatGPT or other large language models)47%i100
First-choice formats
- Discussion with peers64%i100
- Full-length peer-reviewed journal articles61%i100
- Congress presentation or posters29%i100
- Short articles29%i100
- Live or on-demand expert discussions (e.g. Q&A, case discussions)29%i100
- Audio content or podcasts (e.g., on-demand expert interviews, congress recaps)28%i100
When MSL adds most value
- After reviewing relevant data independently, to clarify questions ?or uncertainties30%i100
- To discuss upcoming pipeline developments22%i100
- To discuss complex treatment sequencing or decision-making20%i100
- As a follow-up after I requested medical info19%i100
- As a first introduction to new clinical or trial data17%i100
Most-named KEEs
Full list →- 01Hope Rugo17 mentions
- 02Sara Tolaney7 mentions
- 03Paolo Tarantino6 mentions
- 04Ann Partridge3 mentions
- 05Tiffany Traina3 mentions
- 06Nancy Lin2 mentions